Cargando…
Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain
Background: Chronic back pain due to facet joint syndrome is a common and debilitating condition. Advances in regenerative medicine have shown that autologous unmodified adipose tissue-derived regenerative cells (ADRC) provide several beneficial effects. These regenerative cells can differentiate in...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058908/ https://www.ncbi.nlm.nih.gov/pubmed/36983621 http://dx.doi.org/10.3390/jpm13030436 |
_version_ | 1785016748073811968 |
---|---|
author | Rothoerl, Ralf Tomelden, Junee Alt, Eckhard Udo |
author_facet | Rothoerl, Ralf Tomelden, Junee Alt, Eckhard Udo |
author_sort | Rothoerl, Ralf |
collection | PubMed |
description | Background: Chronic back pain due to facet joint syndrome is a common and debilitating condition. Advances in regenerative medicine have shown that autologous unmodified adipose tissue-derived regenerative cells (ADRC) provide several beneficial effects. These regenerative cells can differentiate into various tissues and exhibit a strong anti-inflammatory potential. ADRCs can be obtained from a small amount of fatty tissue derived from the patient’s abdominal fat. Methods: We report long-term results of 37 patients (age 31–78 years, mean 62.5) suffering from “Facet Joint Syndrome” The pathology was confirmed by clinical, radiological examinations and fluoroscopically guided test injections. Then, liposuction was performed. An amount of 50–100 cc of fat was harvested. To recover stem cells from adipose tissue, we use the CE-certified Transpose RT™ system from InGeneron GmbH. The cells were then injected under fluoroscopic control in the periarticular fat. Follow-up examinations were performed at 1 week, 1 year, and 5 years. Results: Every patient reported improved VAS pain at any follow-up (1 week, 1 year, and 5 years) with ADRCs compared to the baseline. Conclusions: Our observational data indicate that facet joint syndrome patients treated with unmodified adipose tissue-derived regenerative cells experience improved the quality of life in the long term. |
format | Online Article Text |
id | pubmed-10058908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100589082023-03-30 Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain Rothoerl, Ralf Tomelden, Junee Alt, Eckhard Udo J Pers Med Article Background: Chronic back pain due to facet joint syndrome is a common and debilitating condition. Advances in regenerative medicine have shown that autologous unmodified adipose tissue-derived regenerative cells (ADRC) provide several beneficial effects. These regenerative cells can differentiate into various tissues and exhibit a strong anti-inflammatory potential. ADRCs can be obtained from a small amount of fatty tissue derived from the patient’s abdominal fat. Methods: We report long-term results of 37 patients (age 31–78 years, mean 62.5) suffering from “Facet Joint Syndrome” The pathology was confirmed by clinical, radiological examinations and fluoroscopically guided test injections. Then, liposuction was performed. An amount of 50–100 cc of fat was harvested. To recover stem cells from adipose tissue, we use the CE-certified Transpose RT™ system from InGeneron GmbH. The cells were then injected under fluoroscopic control in the periarticular fat. Follow-up examinations were performed at 1 week, 1 year, and 5 years. Results: Every patient reported improved VAS pain at any follow-up (1 week, 1 year, and 5 years) with ADRCs compared to the baseline. Conclusions: Our observational data indicate that facet joint syndrome patients treated with unmodified adipose tissue-derived regenerative cells experience improved the quality of life in the long term. MDPI 2023-02-28 /pmc/articles/PMC10058908/ /pubmed/36983621 http://dx.doi.org/10.3390/jpm13030436 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rothoerl, Ralf Tomelden, Junee Alt, Eckhard Udo Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain |
title | Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain |
title_full | Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain |
title_fullStr | Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain |
title_full_unstemmed | Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain |
title_short | Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain |
title_sort | safety and efficacy of autologous stem cell treatment for facetogenic chronic back pain |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058908/ https://www.ncbi.nlm.nih.gov/pubmed/36983621 http://dx.doi.org/10.3390/jpm13030436 |
work_keys_str_mv | AT rothoerlralf safetyandefficacyofautologousstemcelltreatmentforfacetogenicchronicbackpain AT tomeldenjunee safetyandefficacyofautologousstemcelltreatmentforfacetogenicchronicbackpain AT alteckhardudo safetyandefficacyofautologousstemcelltreatmentforfacetogenicchronicbackpain |